Evofem Biosciences Inc. buy tamam
Start price
26.09.18
/
50%
€60.34
Target price
04.11.21
€105.00
Performance (%)
-85.82%
End price
05.11.21
€8.56
Summary
This prediction ended on 05.11.21 with a price of €8.56. The BUY prediction by tamam for Evofem Biosciences Inc. performed very badly with a performance of -85.82%. tamam has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Evofem Biosciences Inc. | - | - | - | - |
iShares Core DAX® | -0.543% | 1.491% | 13.638% | 16.760% |
iShares Nasdaq 100 | -2.696% | -1.235% | 31.879% | 45.155% |
iShares Nikkei 225® | -2.863% | 2.491% | 12.078% | 7.840% |
iShares S&P 500 | -1.105% | 0.013% | 26.888% | 43.056% |
Comments by tamam for this prediction
In the thread Evofem Biosciences diskutieren
EVFM mit Amphora® zur Schwangerschaftsverhütung
The company's lead candidate is Amphora, a vaginal gel in Phase 3 development as an on-demand hormone-free contraceptive (topline data expected by year-end) and in Phase 2b development for the prevention of STDs chlamydia and gonorrhea.
Kursziel geändert auf 7,0
In the thread Trading Evofem Biosciences
Die von tamam gewählte maximale Laufzeit wurde überschritten